Literature DB >> 21710270

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI.

C Messiou1, D J Collins, S Giles, J S de Bono, D Bianchini, N M de Souza.   

Abstract

OBJECTIVES: To determine whether changes in ADC of bone metastases secondary to prostate carcinoma are significantly different in responders compared with progressors on chemotherapy.
METHODS: Twenty-six patients with known bone metastases secondary to prostate carcinoma underwent diffusion-weighted MRI of the lumbar spine and pelvis at baseline and 12 weeks following chemotherapy. RECIST assessment of staging CT and PSA taken at the same time points were used to classify patients as responders, progressors or stable. ADC (from b = 0,50,100,250,500,750 smm⁻²) and ADC(slow) (from b = 100,250,500,750 smm⁻²) were calculated for up to 5 lesions per patient.
RESULTS: Mean ADC/ADC(slow) in lesions from responders and progressors showed a significant increase. Although the majority of lesions demonstrated an ADC/ADC(slow) rise, some lesions in both responders and progressors demonstrated a fall in ADC beyond the limits of reproducibility.
CONCLUSIONS: Mean ADC is not an appropriate measure of response in bone metastases. The heterogeneity of changes in ADC is likely to be related to the composition of bone marrow with changes that have opposing effects on ADC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21710270     DOI: 10.1007/s00330-011-2173-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  16 in total

1.  Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility.

Authors:  C Messiou; D J Collins; V A Morgan; N M Desouza
Journal:  Eur Radiol       Date:  2011-04-07       Impact factor: 5.315

2.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Authors:  G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

3.  Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations.

Authors:  Carolin Reischauer; Johannes M Froehlich; Dow-Mu Koh; Nicole Graf; Christian Padevit; Hubert John; Christoph A Binkert; Peter Boesiger; Andreas Gutzeit
Journal:  Radiology       Date:  2010-09-09       Impact factor: 11.105

4.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

5.  Quantitative image analysis of vertebral body architecture--improved diagnosis in osteoporosis based on high-resolution computed tomography.

Authors:  A Mundinger; B Wiesmeier; E Dinkel; A Helwig; A Beck; J Schulte Moenting
Journal:  Br J Radiol       Date:  1993-03       Impact factor: 3.039

6.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display.

Authors:  Taro Takahara; Yutaka Imai; Tomohiro Yamashita; Seiei Yasuda; Seiji Nasu; Marc Van Cauteren
Journal:  Radiat Med       Date:  2004 Jul-Aug

Review 7.  Assessment of therapeutic response in patients with metastatic bone disease.

Authors:  Andrew Clamp; Sarah Danson; Huy Nguyen; David Cole; Mark Clemons
Journal:  Lancet Oncol       Date:  2004-10       Impact factor: 41.316

8.  An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone.

Authors:  Kuei C Lee; Sudha Sud; Charles R Meyer; Bradford A Moffat; Thomas L Chenevert; Alnawaz Rehemtulla; Kenneth J Pienta; Brian D Ross
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

9.  Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model.

Authors:  Stefan Rozel; Craig J Galbán; Klaas Nicolay; Kuei C Lee; Sudha Sud; Chris Neeley; Linda A Snyder; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross; Kenneth J Pienta
Journal:  J Cell Biochem       Date:  2009-05-01       Impact factor: 4.429

10.  A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.

Authors:  Kuei C Lee; Deborah A Bradley; Maha Hussain; Charles R Meyer; Thomas L Chenevert; Jon A Jacobson; Timothy D Johnson; Craig J Galban; Alnawaz Rehemtulla; Kenneth J Pienta; Brian D Ross
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

View more
  22 in total

Review 1.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 2.  MRI for response assessment in metastatic bone disease.

Authors:  F E Lecouvet; A Larbi; V Pasoglou; P Omoumi; B Tombal; N Michoux; J Malghem; R Lhommel; B C Vande Berg
Journal:  Eur Radiol       Date:  2013-03-01       Impact factor: 5.315

Review 3.  Imaging and evaluation of patients with high-risk prostate cancer.

Authors:  Marc A Bjurlin; Andrew B Rosenkrantz; Luis S Beltran; Roy A Raad; Samir S Taneja
Journal:  Nat Rev Urol       Date:  2015-10-20       Impact factor: 14.432

Review 4.  Management of metastatic castration-resistant prostate cancer: recent advances.

Authors:  Deborah Mukherji; Andrew Eichholz; Johann S De Bono
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

5.  Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.

Authors:  Raquel Perez-Lopez; Joaquin Mateo; Helen Mossop; Matthew D Blackledge; David J Collins; Mihaela Rata; Veronica A Morgan; Alison Macdonald; Shahneen Sandhu; David Lorente; Pasquale Rescigno; Zafeiris Zafeiriou; Diletta Bianchini; Nuria Porta; Emma Hall; Martin O Leach; Johann S de Bono; Dow-Mu Koh; Nina Tunariu
Journal:  Radiology       Date:  2016-11-22       Impact factor: 11.105

6.  Reduced field of view echo-planar imaging diffusion tensor MRI for pediatric spinal tumors.

Authors:  Lily H Kim; Edward H Lee; Michelle Galvez; Murat Aksoy; Stefan Skare; Rafael O'Halloran; Michael S B Edwards; Samantha J Holdsworth; Kristen W Yeom
Journal:  J Neurosurg Spine       Date:  2019-07-05

Review 7.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044

8.  Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values.

Authors:  C Messiou; D J Collins; V A Morgan; D Bianchini; J S de Bono; N M de Souza
Journal:  Skeletal Radiol       Date:  2013-11-24       Impact factor: 2.199

Review 9.  Therapy response with diffusion MRI: an update.

Authors:  Lauren J Bains; Martin Zweifel; Harriet C Thoeny
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

10.  Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.

Authors:  A Som; S-M Tu; J Liu; X Wang; W Qiao; C Logothetis; P G Corn
Journal:  Br J Cancer       Date:  2012-10-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.